Lerapolturev is under clinical development by Istari Oncology and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase II drugs for High-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lerapolturev LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lerapolturev overview
Lerapolturev is under development for the treatment of recurrent glioblastoma (recurrent grade IV glioma), supratentorial glioma, high grade glioma, melanoma, hormone positive breast cancer, anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, ependymoma, bladder cancer, urothelial carcinoma and non-muscle invasive bladder cancer. The vaccine comprises of live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. The vaccine is administered through intra-tumoral, intravesical and intralesional route.
It was also under development for solid tumor, urothelial carcinoma and non-muscle invasive bladder cancer, head and neck cancer squamous cell carcinoma, oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer, laryngeal cancer, triple-negative breast cancer (TNBC), breast cancer, human epidermal growth factor receptor 2 positive breast cancer (HER2+ breast cancer), melanoma, recurrent glioblastoma multiforme (GBM), oligodendroglioma, ependymoma, medulloblastoma, atypical teratoid rhabdoid tumor, atypical teratoid rhabdoid tumor, muscle invasive bladder cancer (MIBC), gastric cancer and esophageal cancer
Istari Oncology overview
Istari Oncology is developing novel immunotherapies for the treatment of solid tumors. The company is headquartered in Durham, North Carolina, the US.
For a complete picture of Lerapolturev’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
